Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumours

Official Title

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumours


This study is an open-label, international, multi-centre, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumours, which harbor the NRG1 gene fusion.

Trial Description

Primary Outcome:

  • Objective Response Rate

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society